Novel therapies for inflammatory diseases
     of the digestive system

Current Projects: LT-02 for the treatment of Ulcerative colitis

Lipid Therapeutics licenses rights to its novel therapy for ulcerative colitis to Nestlé Health Science

Nestlé Health Science to develop and commercialise LT-02 worldwide, except in Europe and Australia

 


 

Neue Therapien für Entzündungskrankheiten
des Verdauungssystems     

Gegenwärtige Projekte: LT-02 für die Behandlung von Colitis ulcerosa